{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"188","upperLimit":"275","value":"223"},{"groupId":"OG001","lowerLimit":"54","upperLimit":"112","value":"57"},{"groupId":"OG002","lowerLimit":"63","upperLimit":"165","value":"113"},{"groupId":"OG003","lowerLimit":"56","upperLimit":"154","value":"110"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"107"},{"groupId":"OG003","value":"23"}],"units":"Participants"}],"description":"Progression-Free Survival (PFS) is calculated as 1+ the number of days from the first dose of study drug to disease progression by RECIST, as determined by the investigator or death due to any cause, whichever occurs first. Progression is defined using RECIST v1.1, as at least a 20% increase in the sum of the longest diameter of target lesions, or a measureable increase in a non-target lesion, or the appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with a deleterious BRCA mutation detected in their tumor.","id":"OG000","title":"Part 2: tBRCA"},{"description":"Patients without a BRCA mutation in their tumor, but have high LOH.","id":"OG001","title":"Part 2: Non-tBRCA LOH+"},{"description":"Patients without a BRCA mutation in their tumor, but have low LOH.","id":"OG002","title":"Part 2: Non-tBRCA LOH-"},{"description":"Patients without a BRCA mutation in their tumor, and have unknown LOH due to missing results and/or failed test result(s).","id":"OG003","title":"Part 2: Non-tBRCA LOH Unknown"}],"paramType":"MEDIAN","populationDescription":"Safety population by HRD subgroups: Consist of all Part 2 patients who received at least one dose of rucaparib.","reportingStatus":"POSTED","timeFrame":"Assessments every 8 weeks from C1D1 until disease progression, death or withdrawal of consent. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3 years.","title":"Progression-free Survival (PFS) According to RECIST v1.1 in Molecularly-defined HRD Subgroups (Part 2 of Study)","type":"SECONDARY","unitOfMeasure":"Days"}